Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed advanced, recurrent, or metastatic colorectal adenocarcinoma~* Resected CNS metastases stable greater than 1 month after completion of radiotherapy for CNS metastases eligible~  * No existing CNS metastases allowed~* Measurable disease~  * At least 1 dimension as at least 20 mm with conventional techniques OR~ * At least 10 mm with spiral CT scan~ * No truly nonmeasurable lesions:~    * Bone lesions~   * Leptomeningeal disease~   * Lymphangitis cutis/pulmonis~   * Abdominal masses not confirmed and followed by imaging techniques~   * Cystic lesions~* Must have progressed on at least 1 prior, but no more than 2 prior, fluorouracil and/or irinotecan containing treatment regimens for metastatic colorectal cancer~* Must have documented HER-2/neu overexpression by immunohistochemistry staining~  * Staining score at least 2+~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Granulocyte count at least 1,500/mm3~* Platelet count at least 100,000/mm3~Hepatic:~* Bilirubin no greater than 2.0 mg/dL~* AST no greater than 2.5 times upper limit of normal~Renal:~* Creatinine normal OR~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No history of cardiac ischemia or congestive heart failure~* LVEF at least 50% by ECG or MUGA~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No concurrent second malignancy except nonmelanoma skin cancers or carcinoma in situ of the cervix unless completed therapy and considered to be at less than 30% risk of relapse~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* No prior platinum containing chemotherapy~* At least 3 weeks since prior chemotherapy and recovered~* No other concurrent chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 3 weeks since prior radiotherapy and recovered~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination Chemotx (Type: EXPERIMENTAL): Combination chemotherapy for metastatic colorectal cancer in patients who have disease progression after 5-FU and/or irinotecan-containing therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).